NCT02534922View on ClinicalTrials.gov

Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer

PHASE1UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Interventions
BIOLOGICAL

Prolanta, a human prolactin receptor antagonist

Daily subcutaneous dosing

Trial Locations (1)

29605

RECRUITING

ITOR/GHS, Greenville

Sponsors

Lead Sponsor

Oncolix, Inc.
All Listed Sponsors
lead

Oncolix, Inc.

INDUSTRY